Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2021-04-06 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于全资子公司参与认购基金份额暨对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about its wholly-owned subsidiary's participation in a fund subscription and external investment. It details the investment overview, fund information, partners, independent directors' opinions, supervisory board review, impact on the company, and risk warnings. The content focuses on a specific investment transaction and related approvals, not on financial results, earnings, or management changes. It is not a full financial report, earnings release, or management discussion. It is an announcement of a capital investment activity by the company. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is about 5,386 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report.
2021-04-06 Chinese
易明医药2020年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a "2020年度业绩快报" which translates to "2020 Annual Performance Express Report" or "2020 Annual Results Brief." It contains preliminary financial data for the year 2020, including revenue, profit, net income, earnings per share, and asset data. The text explicitly states that the data is preliminary, internally audited but not yet audited by an external accounting firm, and may differ from the final annual report. The document is relatively short (1492 characters) and serves as a quick announcement of financial results rather than a full detailed annual report. It includes key financial highlights and some management commentary on performance but lacks the comprehensive financial statements and detailed disclosures typical of a full Annual Report (10-K). This type of document is best classified as an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. FY 2020
2021-04-06 Chinese
独立董事关于第二届董事会第十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding matters discussed at the company's 18th board meeting of the second board term. It discusses the legality and compliance of a non-public stock issuance, the appointment of a new financial director, and investment decisions by a subsidiary. The document references relevant laws and regulations and provides an independent opinion on these corporate governance matters. It does not contain financial statements or detailed financial results, nor is it a transcript or presentation. It is a formal board-related opinion document, which fits best under Board/Management Information (MANG) as it relates to board meeting matters and management appointments.
2021-04-06 Chinese
关于最近五年被证券监管部门和交易所处罚或采取监管措施情况的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement from a company regarding the absence of penalties or regulatory measures taken against it in the past five years by securities regulatory bodies or exchanges. It mentions the company's intention to apply for a non-public stock issuance and compliance with relevant laws. The document is brief (531 characters) and does not contain financial statements or detailed financial data. It is an official regulatory announcement related to compliance and regulatory status, not a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-04-06 Chinese
关于本次非公开发行A股股票摊薄即期回报及采取填补措施、相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding a non-public issuance of shares and its impact on immediate earnings dilution and the measures taken to compensate for this dilution. It includes detailed financial assumptions, impact analysis on earnings per share, and commitments by the board and controlling shareholders to uphold these measures. The document is not a full financial report but rather a regulatory announcement about a capital financing event and related shareholder protections. It does not contain comprehensive financial statements or quarterly/yearly financial results but focuses on the capital raising and dilution impact. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2021-04-06 Chinese
关于公司前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by the company 西藏易明西雅医药科技股份有限公司, including amounts raised, usage, changes in investment projects, idle funds usage, and economic benefits realized. It references compliance with regulations from the China Securities Regulatory Commission regarding the reporting of previous fundraising usage. The document is comprehensive, contains financial figures, project details, and management approvals, and is not merely an announcement or a brief summary. It is not an annual report, earnings release, or management discussion but specifically focuses on the use of capital raised in a prior fundraising event. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage. The document length (7739 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-04-06 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.